Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.05 USD
-0.02 (-0.97%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $2.06 +0.01 (0.49%) 7:48 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Poseida Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 212 | 283 | 206 | 309 | 125 |
Receivables | 9 | 9 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 7 | 8 | 5 | 2 |
Total Current Assets | 226 | 299 | 214 | 314 | 127 |
Net Property & Equipment | 19 | 22 | 22 | 23 | 11 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 6 | 6 | 6 | 6 | 6 |
Deposits & Other Assets | 1 | 1 | 2 | 4 | 3 |
Total Assets | 274 | 352 | 269 | 371 | 147 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 9 | 1 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 31 | 26 | 24 | 24 | 14 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 31 | 20 | 5 | 0 | 0 |
Total Current Liabilities | 71 | 54 | 43 | 30 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 17 | 21 | 9 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 59 | 58 | 29 | 29 | 26 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 6 | 6 | 25 | 26 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 170 | 164 | 113 | 110 | 74 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 222 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 698 | 659 | 563 | 544 | 3 |
Retained Earnings | -594 | -471 | -407 | -282 | -152 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 104 | 188 | 156 | 262 | 73 |
Total Liabilities & Shareholder's Equity | 274 | 352 | 269 | 371 | 147 |
Total Common Equity | 104 | 188 | 156 | 262 | -150 |
Shares Outstanding | 95.60 | 85.90 | 62.50 | 61.80 | NA |
Book Value Per Share | 1.08 | 2.18 | 2.50 | 4.24 | 0.00 |
Fiscal Year End for Poseida Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 212 | 239 | 215 | 247 |
Receivables | NA | 9 | 9 | 12 | 8 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 5 | 4 | 5 |
Total Current Assets | NA | 226 | 253 | 230 | 261 |
Net Property & Equipment | NA | 19 | 20 | 21 | 22 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 6 | 6 | 6 | 6 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 274 | 302 | 281 | 314 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 2 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 31 | 24 | 22 | 20 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 31 | 45 | 20 | 20 |
Total Current Liabilities | NA | 71 | 77 | 50 | 49 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 17 | 19 | 8 | 19 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 59 | 58 | 58 | 58 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 2 | 6 | 6 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 170 | 179 | 146 | 156 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 698 | 693 | 673 | 667 |
Retained Earnings | NA | -594 | -569 | -537 | -510 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 104 | 124 | 135 | 158 |
Total Liabilities & Shareholder's Equity | NA | 274 | 302 | 281 | 314 |
Total Common Equity | 0 | 104 | 124 | 135 | 158 |
Shares Outstanding | 96.40 | 95.60 | 86.90 | 86.70 | 86.70 |
Book Value Per Share | 0.00 | 1.08 | 1.42 | 1.56 | 1.82 |